Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Feb 24, 2019 11:48am
63 Views
Post# 29405871

RE:RE:RE:RE:RE:F4 formulation

RE:RE:RE:RE:RE:F4 formulation
Good point.

Perhaps reps can point to the CDC as to why undetectable is the goal.

https://www.cdc.gov/hiv/risk/art/index.html



jfm1330 wrote: An interesting point in the Q&A period made by Christian Marsolais is the fact that some doctors are managing their MDR patients to keep them with dectectable viral load between 200 and 1000, while Trogarzo would allow to bring their viral load to an undetectable level or very close to it.

This is in line with what I put forward here last week, which is the fact that doctors will need to start Trogarzo earlier and not wait until all cheaper options are not working at all. There is no reasons to keep a patient with detectable viral load when a drug with a new mechanism of action can solve the problem and bring the viral load to undetectable level or very close to it. MSL and sales reps need to do education and Thera need to connect directly with patients for them to ask for Trogarzo.


Bullboard Posts